Results 81 to 90 of about 2,285,787 (260)
, 2018 Wei Zhang,1 Kimberly R Jordan,2 Brian Schulte,3 Enkhtsetseg Purev1 1Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2Division of Immunology, Department of Medicine, University of Colorado ...
Zhang W, Schulte B, Purev E, Jordan KR
core
FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape
Advanced Science, EarlyView.FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu +14 more
wiley +1 more source
CAR-based cell therapy for autoimmune diseases
Frontiers in ImmunologyChimeric antigen receptor (CAR)-based cell therapies, initially designed for oncology, are rapidly advancing as a novel and highly targeted approach for the treatment of autoimmune diseases (AIDs).
Xiu Li +5 more
doaj +1 more source
, 2023 Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies are dependent upon designed transmembrane proteins to bind target antigens and stimulate an immune response.
Jonah Cheung +5 more
core +1 more source
Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Advanced Science, EarlyView.Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao +2 more
wiley +1 more source
Advanced Science, EarlyView.Multifunctional oral delivery system—L. reuteri@ZGM—act as both a carrier and therapeutic adjuvant, providing ROS scavenging, and mucin‐interactive properties tailored to the IBD microenvironment. This bioactive gel safeguards L. reuteri from gastric degradation, enhances mucosal adhesion, and promotes long‐term retention at inflamed sites, thereby ...
Mengyun Peng +8 more
wiley +1 more source
Chimeric antigen receptor modified T-cells for cancer treatment
Chronic Diseases and Translational Medicine, 2018 T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory ...
Xiao Han, Yao Wang, Wei-Dong Han
doaj +1 more source
Advanced Science, EarlyView.Magnetically guided macrophage immunobots integrate active tumor targeting with immunometabolic therapy. After systemic administration, magnetic actuation enhances immunobot retention and tumor penetration, while LPS‐functionalized FePt microrollers sustain M1‐like polarization through inflammatory and iron‐amplified oxidative signaling and trigger ...
Xirui Zeng +7 more
wiley +1 more source
Nature Communications, 2018 Engineered T cells with chimeric antigen receptor (CAR) are emerging as an effective cancer therapy. Here the authors show that CAR T cells recognizing self-MHC can be ‘tuned’ ex vivo via CAR downregulation and CAR T cell death to generate a CAR T pool ...
Chungyong Han +13 more
doaj +1 more source
Synthetic immunology: T-cell engineering and adoptive immunotherapy
Synthetic and Systems Biotechnology, 2018 During the past decades, the rapidly-evolving cancer is hard to be thoroughly eliminated even though the radiotherapy and chemotherapy do exhibit efficacy in some degree. However, a breakthrough appeared when the adoptive cancer therapy [1] was developed,
Wen Si, Cheng Li, Ping Wei
doaj +1 more source